Liquidia (LQDA) Cash from Operations Growth (3y) (2023 - 2026)

Liquidia (LQDA) Cash from Operations Growth (3y) (2023 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Ops. Growth (3y) (Qtr)
1 Teva Pharmaceutical Industries 38.77 Bn 35.04 Bn 1.97 Bn 34.90%
2 Zoetis 34.11 Bn 32.16 Bn 1.62 Bn -9.94%
3 United Therapeutics 23.68 Bn 21.53 Bn 648.10 Mn 7.32%
4 Aurora Cannabis 16.48 Bn 16.40 Bn 33.43 Mn -
5 Neurocrine Biosciences 16.19 Bn 14.88 Bn 800.70 Mn 46.81%
6 Elanco Animal Health 11.44 Bn 11.01 Bn 785.00 Mn 27.85%
7 Alkermes 7.28 Bn 6.77 Bn -116.06 Mn -98.15%
8 Lantheus Holdings 6.48 Bn 5.98 Bn 230.92 Mn 4.87%
9 Hims & Hers Health 6.35 Bn 5.60 Bn 396.79 Mn 111.22%
10 Liquidia 5.74 Bn 5.52 Bn 121.79 Mn 102.19%

Historic Data

Download Data
DateValue
Mar 31, 2026 102.19%
Dec 31, 2025 126.45%
Sep 30, 2025 -19.16%
Jun 30, 2025 -67.32%
Mar 31, 2025 -46.38%
Dec 31, 2024 -40.16%
Sep 30, 2024 -62.63%
Jun 30, 2024 -40.00%
Mar 31, 2024 -26.15%
Dec 31, 2023 -4.29%
Sep 30, 2023 2.59%
Jun 30, 2023 24.85%
Mar 31, 2023 16.33%